Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Search Site

Over 2,750 Pages of
Hepatitis C Info, Here:
Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China
1 Department of Epidemiology, Second Military Medical University, Shanghai, China 2 Department of Acute Infectious Diseases, Center for Disease Control and Prevention, Shanghai, China 3 Department of Infectious Diseases, The 1st Affiliated Hospital,

Hepatitis C virus entry: possible targets for therapy
Institute for Biomedical Research, University of Birmingham, Birmingham, UK Correspondence to: Professor J A McKeating, Institute for Biomedical Research, The Medical School, Vincent Drive, Birmingham B15 2TT, UK; j.a.mckeating@bham.ac.uk The first 150

Hepatitis A outbreak spreads at Consolidated School
Other cases possible Today's most viewed articles Was it really 'obvious' McKey would win ?America?s Next Top Model?? - 11/19/2008 Police: Second worker stole thousands from York business - 11/19/2008 Hugh Jackman robs Christian Bale of 'Sexiest

UPDATES AND COMMENTARY RSS Feed

Who Will Respond to Hepatitis C Treatment
The relatively new field of proteomics may be able to predict who will respond to Hepatitis C therapy - before treatment even begins....

Antivirals Combined Without Interferon: New Trial
Three companies unite to begin an innovative Hepatitis C trial, where two oral antiviral drugs will be combined in the absence of interferon....

HCV May Be Able to Be Cleared from Both Blood and Liver
Viral clearance doubled in a Hepatitis C Phase II trial during standard therapy when coupled with GlobeImmune's GI-5005. Because Hepatitis C must be eradicated not just from the blood, but also the liver, GI-5005's ability to speed the clearance rate...
Safety and Immunogenicity of
Hepatitis A Vaccine in Patients With Chronic Liver Disease

table  3.   Seroconversion Rates and GMT
Timing (n) Seroconversion
GMC 95% Confidence Interval
(n) %
Group1: healthy adults month 1  185 172 93.0 175 150-206
   month 2  186 162 87.1 100 87-115
month 6  180 132 73.3 74 63-87
month 7  167 164 98.2 1315 1086-1593
Group 2: chronic hepatitis B month 1  43 36 83.7 93 68-127
   month 2  46 33 71.7 69 49-97
month 6  45 23 51.1 43 31-60
month 7  44 43 97.7 749 519-1080
Group 3: chronic hepatitis C month 1  99 73 73.7* 77 60-98
   month 2  97 55 56.7* 47 38-58
month 6  93 35 37.6* 32 26-40
month 7  87 82 94.3 467 345-631
Group 5: others month 1  65 54 83.1* 112 83-149
   month 2  66 48 72.7* 64 50-81
month 6  63 40 63.5 44 36-53
month 7  63 60 95.2 562 403-783

NOTE. Month 1, etc.: blood sample obtained one month after dose 1, etc. Seroconversion rates in each group of CLD patients were compared with that in healthy subjects by Fisher's Exact test. For calculation of GMCs, negative values were given an arbitrary value of one half the cut-off. 95% confidence interval = lower and upper 95% confidence interval.
Abbreviations: GMC, geometric mean anti-HAV concentration; others, CLD of etiology other than hepatitis B or C; seroconversion, seropositive for anti-HAV with titer 33 mIU/mL.
* P < .01.

Return To Article
  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 20 Nov 2008